Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling

Src family tyrosine kinase (SFK) activation is associated with ovarian cancer progression. Therefore, SFKs are targets for the development of potential treatments of ovarian cancer. Dasatinib is a tyrosine kinase inhibitor that targets SFK activity, and is used for the treatment of B cell and Abelso...

Descripción completa

Detalles Bibliográficos
Autores principales: XIAO, JUAN, XU, MANMAN, HOU, TENG, HUANG, YONGWEN, YANG, CHENLU, LI, JUNDONG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526065/
https://www.ncbi.nlm.nih.gov/pubmed/25975261
http://dx.doi.org/10.3892/mmr.2015.3784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526065/
https://www.ncbi.nlm.nih.gov/pubmed/25975261
http://dx.doi.org/10.3892/mmr.2015.3784

Ejemplares similares